by Paul Saltet | Jan 23, 2024 | Uncategorized
HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq 1st institutional round for HEPHAISTOS-Pharma, getting on track to bring its lead product ONCO-Boost to the clinic. ONCO-Boost is a novel class of TLR4...
by Paul Saltet | Dec 12, 2023 | Uncategorized
We are pleased to announce that HEPHAISTOS-Pharma has been awarded a Sanofi’s Golden Ticket 2023, winning a year’s free lab space at BioLabs @Hôtel-Dieu (France) to explore the application of their technology in developing new effective adjuvantation for mRNA...
by Paul Saltet | Nov 12, 2023 | Uncategorized
We are very proud to announce that we are winners of the #EIC_Accelerator grant from the European Innovation Council October 30th 2023. Winners of the EIC accelerator grant have been announced. 47 winning innovative projects have been awarded all over Europe among...
by Paul Saltet | Jan 16, 2023 | Uncategorized
We are very proud to announce that we are winners of the #iNov France2030 Innovation Competitions For this 9th edition, 53 winning innovative projects will be supported by the State via #France2030 for a total amount of €56.3M. The i-Nov innovation competition aims to...
by Paul Saltet | Sep 1, 2022 | Uncategorized
The European Medicines Agency (EMA) has granted Orphan Drug Designation to ONCO-Boost (HEPHAISTOS-Pharma) as treatment for osteosarcoma. Paris, France, September 1st, 2022, 7:00 pm CET. HEPHAISTOS-Pharma a French Biotech company developing a new class of...
